Overview

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

This single-armed study aims to investigate the safety and efficacy of sonrotoclax in combination with intensive chemotherapy in subjects with newly diagnosed AML. Subjects will be stratified based on the genetic risk classification of 2022 European LeukemiaNet (ELN) recommendations and MRD status to receive specific consolidation therapy after the induction therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborators:

BeiGene
Ruijin Hospital

Treatments:

Azacitidine
Cytarabine
Daunorubicin
Idarubicin